Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Tomoaki Ueda,Kentaro Fukushima,Shinsuke Kusakabe,Koki Yoshida, Makiko Suga,Ritsuko Nakai,Midori Koike,Akihisa Hino,Keigo Akuta,Jun Toda,Yasuhiro Nagate,Yukiko Doi,Jiro Fujita,Takafumi Yokota,Naoki Hosen

Leukemia Research Reports（2022）

引用 2|浏览2

暂无评分

摘要

•The outcome of R/R Ph+ALL is dismal.•Single cycle of Inotuzumab ozogamicin could achieve CR without VOD/SOS.•Blinatumomab could achieve and keep MRD negativity without CRS.•InO-Blina is effective and safe for R/R Ph+ALL as a bridging regimen before allo-SCT.

查看译文

关键词

Philadelphia chromosome-positive acute lymphoblastic leukemia,Allogeneic stem cell transplantation,Inotuzumab ozogamicin,Blinatumomab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要